China News Service, Beijing, May 1 (Reporter Chen Kangliang) According to the latest data disclosed by the China Association of Listed Companies, in 2021, China's listed companies will achieve a total operating income of 64.97 trillion yuan, accounting for 56.81% of last year's GDP. A year-on-year increase of 19.81%; net profit was 5.3 trillion yuan, a year-on-year increase of 19.56%.

　　The relevant person in charge of the China Association of Listed Companies said that the role of China's listed companies as the "power source" for economic growth has continued to strengthen, and their status as the "basic market" of the real economy has been consolidated.

　　Cheng Fengchao, president of the Zhongguancun Guorui Finance and Industrial Development Research Association, said in an interview with a reporter from China News Agency on May 1 that overall, the operating performance of Chinese listed companies continued to improve, and the quality of the company improved steadily.

However, affected by factors such as the new crown pneumonia epidemic, the development quality of listed companies, especially the profitability, needs to be further improved.

　　Statistics show that in 2021, the net profit of Chinese listed companies will have significant industry differentiation characteristics.

The top three industries in terms of profits are finance, manufacturing and mining, which together contribute nearly 88% of the overall net profit of listed companies.

Affected by factors such as the epidemic situation, the real estate, leasing and business services industries have not yet established a solid foundation for the company's profit recovery, resulting in a continuous decline in net profit.

　　Cheng Fengchao pointed out that in 2021, China's non-financial listed companies' R&D investment will total about 1.17 trillion yuan, a year-on-year increase of 27.90%, accounting for 2.13% of operating income, and listed companies will pay more attention to R&D.

However, in general, there is still a big gap between R&D investment and technology companies in developed capital markets. Taking the healthcare industry as an example, the median ratio of R&D investment to operating income in the pharmaceutical and biological industry of A shares is 4.57%, while that of US stocks The median ratio of R&D investment to operating income in the healthcare industry is 83.94%.

　　Statistics also show that in 2021, China will add 524 new listed companies, and the number of companies will increase to 4,682 at the end of the year, with a total market value of 96.53 trillion yuan, ranking second in the world.

Among them, the number of companies listed on the Shanghai, Shenzhen and Beijing stock exchanges was 2031, 2569 and 82 respectively.

　　Looking forward to 2022, Cheng Fengchao believes that opportunities and challenges for Chinese listed companies coexist.

The Politburo meeting of the Central Committee of the Communist Party of China held on April 29 clarified the general tone, general direction and general strategy of China's economic development at present and in the future. This is a major opportunity for the reform and development of Chinese listed companies; Conflicts and the implementation of trade unilateralism by some Western countries have a great impact on the production and operation of listed companies, and the difficulties cannot be underestimated.

In the coming period, the main tone of the development of listed companies should be to insist on promoting independent innovation on the basis of open innovation, try to create a more open, inclusive, mutually beneficial and sharing international scientific and technological cooperation atmosphere, and strive to develop both domestic and international markets.

(Finish)